Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bellus Health Inc.

www.bellushealth.com

Latest From Bellus Health Inc.

Finance Watch: SpringWorks, Satsuma Launch IPOs; BioNTech Filing Shows US-China Trade War Impact

BioNTech has plenty of cash and is gearing up for an IPO, but money from a Hong Kong investor is in limbo. Plus, Satsuma and SpringWorks bring US IPO total to 34 this year, Fate's FOPO raises $150.5m and Pharvaris brings in $66m.

Financing Business Strategies

Finance Watch: Here Come The IPOs Again As Bellus Raises $70m And Vir Joins The Queue

Public Company Edition: Bellus launched the first biopharma IPO in the US since mid-July and Vir Biotechnology, run by former Biogen CEO George Scangos, wants to raise $100m. Also, Turning Point's $202.5m offering and Zafgen's strategic review.

Financing Business Strategies

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018

The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.

Financing Business Strategies

Alzheon IPO To Fund New Phase III Trialling Of Failed Alzheimer's Drug

Alzheon tells prospective investors it believes beta-amyloid blocker ALZ-801 can succeed in pivotal trials by treating APOE4 subgroup.

Analysis Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Respiratory, Pulmonary
  • Alias(es)
  • Neurochem Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Bellus Health Inc.
  • Senior Management
  • Roberto Bellini, Pres. & CEO
    François Desjardins, VP, Fin.
    Denis Garceau, PhD, SVP, Drug. Dev.
    Tony Matzouranis, VP, Bus. Dev.
    Catherine Bonuccelli, MD, CMO
  • Contact Info
  • Bellus Health Inc.
    Phone: (450) 680-4500
    275 Armand-Frappier Blvd.
    Laval, H7V 4A7
    Canada
UsernamePublicRestriction

Register